

Therapy for Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Choukri Ben Mamoun

Founder

Professor of Medicine, Microbial Pathogenesis and Pathology

Yale



PKAN

Rare neurodegenerative disease

- Parkinsonism
- Dementia
- Inability to control muscle function
- Death

Autosomal recessive:

■ Pantothenate Kinase 2 (*PANK2*)



https://www.dailymail.co.uk

6/1/23 Confidential




NBIA Conference Houston 05/ 2023






PKAN – NBIA

Iron accumulation in basal ganglia





PanK2 loss of function → PKAN




PANK2


- Mitochondrial PanK enzyme
- The major active PANK isoform in the human brain

6/1/23




PROBLEM








Disrupted





PROBLEM & SOLUTION



Confidential



HUMAN PANK3 ACTIVATORS VTACs

Pank Modulators

Screening cascade

156,593 Compounds

Hits: 268

Inhibition of Fungal PanK No inhibition of Human PanK3

Med. Chem. Triage: 76

Chemotypes: 12

415 analogs

86 PTZ

9 ACT

IP: Yale 63/043,534 valid until 2040

1 Completed

Assay Development

Developed ATP-based highthroughput screen

2 Completed

PanK modulators

156,000 compounds screened

3 Completed

Lead Identification

14 activators of human PanK3

VTAC1-14: AC₅₀ in the nM range

4 In Progress

Preclinical Studies

Cell-based assays Animal models of PKAN

5 Future

Clinical Testing

Conduct clinical trials

FUNDING

Program in
Therapeutics for CT
Health

2017 - 2020


(\$736,000)

YBFI \$300K: 07/21 – 07/24

NDF: \$700K: 07/23-06/25


Series A $2023 \rightarrow$


Confidential



VTACs Modes of Activation

Active site activator $AC_{50} = 49 \text{ nM}$ CLogP = 2.18 MW: 382.466 No toxicity Log [VTAC-1] M







Confidential





VTACs superiority over pantazines (Direct vs Orthosteric activators)





VTACs: Long half life and CNS exposure









Cell-based Assays and Animal Models

In vivo efficacy ongoing





SUMMARY

Novel Activators Novel mode of action

Novel strategy

IP → 2040 Series A

Milestone
IND + Phase I

Goal
Treatment for PKAN




With permission from the families

HOPE IS A WAKING DREAM

ARISTOTLE



With permission from the families



Thank You

choukri.benmamoun@yale.edu

choukri.benmamoun@virtustherapeutics.com

6/1/23 Confidential



VIRTUS STRUCTURE



Choukri Ben Mamoun, PhD. Yale
Founder
Professor of Medicine and
Microbial Pathogenesis



Stephen Chang:
Scientific Advisor
Ex-CEO, president, chairman of the board of multiple biotech companies



Mark S. Plummer, PhD
Scientific Advisor/Consultant
Medicinal Chemistry



Aaron Nilsen, PhD OHSU
Scientific Advisor/Consultant
Medicinal Chemistry



Jaime Grutzendler, MD Yale
Scientific Advisor
Professor of Neuroscience and
Neurology



John Puziss,
Yale Ventures
IP contact

Yale